Many neurological diseases are still regarded as scientific mysteries. Given the complexities that exist within our neurological makeup, figuring out how diseases interact with the nervous system is often very challenging.

Dr. Karen S. Ho is the Senior Director of Translational Medicine at Clene Inc. Clene is a "clinical-stage" biopharmaceutical organization that commits itself to the innovative treatment of neurodegenerative diseases. They do so using nanotherapeutics to target specific "cellular energy impairments" that are persistently present in many diseases.

Tune in now to discover:

• The neurodegenerative diseases that Clene focuses on.
• What Amyotrophic Lateral Sclerosis (ALS) is, and who can be affected by it.
• Why neurodegenerative diseases tend to show up as we age.
• The particulars of Clene's drug, and how it works.

Offer: This episode is sponsored by Bowmar Nutrition. To receive a 5% discount, use the code GENIUS5 at checkout. Go to BowmarNutrition.com to shop now! Is Clene part of the future of pharmaceutical research? Dr. Karen S. Ho is certainly the person to ask! Listen now to learn more about Clene and its mission to effectively treat neurological disorders.

Find out more about Clene Inc. and its therapeutic approach at clene.com.

Episode also available on Apple Podcast: http://apple.co/30PvU9C Episode also available on Spotify: https://spoti.fi/3znPGu5